


PHARMACEUTICAL 2022

Immix Biopharma Inc. Rank 293 of 466







Immix Biopharma Inc. Rank 293 of 466

The relative strengths and weaknesses of Immix Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immix Biopharma Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 106% points. The greatest weakness of Immix Biopharma Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 249% points.

The company's Economic Capital Ratio, given in the ranking table, is 71%, being 6.7% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	18,186
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	202
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-6.5
Other Expenses	6.0
Other Liabilities	0
Other Net Income	-23,026
Other Revenues	0
Property and Equipment	5.7
Research and Development	127
Selling, General and Administrative Expense	1,225

Output Variable	Value in 1000 USD
Assets	18,192
Liabilities	202
Expenses	1,358
Revenues	0
Stockholders Equity	17,990
Net Income	-24,384
Comprehensive Net Income	-24,387
Economic Capital Ratio	71%

